PHAXIAM Therapeutics: Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext.
Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted will likely not allow for any reimbursement of shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.phaxiam.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
4 hours ago
- Hamilton Spectator
U.S., Canadian markets move higher as investors shrug off tariff ‘noise'
Canada's main stock index edged up and U.S. markets climbed as investors tried to tune out the latest noise from U.S. President Donald Trump's tariff war. 'I think everybody's taking a wait-and-see approach,' said Allan Small, senior investment adviser at iA Private Wealth, referring to worldwide 'reciprocal' tariffs on pause for at least another month. 'It would be a very bad thing for the United States to reinstate these large tariffs. So I think the market is saying that's not going to happen and moving higher based on anticipating something good coming out of some trade negotiations.' The S&P/TSX composite rose 37.68 points to 26,426.64. The Canadian market has benefited recently from strength in gold — a safe haven investors tend to flee to during rocky times — as well as energy and financials, Small said. In New York, the Dow Jones industrial average was up 214.16 points at 42,519.64. The S&P 500 index was up 34.43 points at 5,970.37, while the Nasdaq composite was up 156.34 points at 19,398.96. 'It's interesting that the market is shrugging off a lot of the noise coming out of Washington with respect to the increase in steel and aluminum tariffs,' Small said. In March, Trump imposed 25 per cent tariffs on steel and aluminum imports to the United States. Trump announced his intention to double the duties at a steel plant on Friday. Canada is the largest steel supplier to the United States, accounting for nearly 25 per cent of all imports in 2023. As Canadian officials were preparing for meetings in Washington on Tuesday, White House press secretary Karoline Leavitt said Trump would sign an executive order to increase the duties to 50 per cent. U.S. markets are heavily swayed by moves in big tech stocks like Apple, Nvidia and Meta. And those stocks tend to in turn be driven largely by the latest tariff news. 'Trade's ruling the day and the one sector that seems to be heavily affected is tech,' Small said. 'As long as the U.S. is talking to China, tech seems to be doing OK.' Small said it appears the global trade war is entering a new phase centred around negotiating deals, Small added. Investors, meanwhile, are becoming immune to the almost daily back-and-forth. 'The president seems to come out swinging every time, swinging for the fences, asking for this, that and the other,' Small said. 'And then in the end he seems to pull back and it ends up being not as scary as initially thought.' North of the border, the Bank of Canada is set to announce its latest interest rate decision on Wednesday. Small said it's likely the central bank will hold off cutting rates until it can get a clearer picture of Canada's economic health, once second-quarter GDP numbers are in. 'But I think it can go either way at this point.' Statistics Canada is also set to release the May jobs report on Friday, and Small said that should provide a more current view of how well the Canadian economy is faring. The Canadian dollar closed at 72.87 cents US compared with 72.96 cents US on Monday. The July crude oil contract was up 89 cents US at US$63.41 per barrel and the July natural gas contract was up three cents US at US$3.72 per mmBTU. The August gold contract was down US$20.10 at US$3,377.10 an ounce and the July copper contract was down two cents US at US$4.83 a pound. This report by The Canadian Press was first published June 3, 2025. Companies in this story: (TSX: GSPTSE, TSX: CADUSD)
Yahoo
4 hours ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
